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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.010Integrin a7 (ITGA7) is a tumor-suppressor gene that is critical for suppressing the growth of malignant
tumors; however, the mechanisms allowing ITGA7 to suppress the growth of cancer cells remain unclear.
Herein, we show that ITGA7 binds to tissue inhibitor of metalloproteinase 3 (TIMP3) in prostate cancer
cells. The ITGA7-TIMP3 binding led to a decreased protein level of tumor necrosis factor a, cytoplasmic
translocation of NF-kB, and down-regulation of cyclin D1. These changes led to an accumulation of cells
in G0/G1 and a dramatic suppression of cell growth. Knocking down TIMP3 or ITGA7/TIMP3 binding
interference largely abrogated the signaling changes induced by ITGA7, whereas a mutant ITGA7 lacking
TIMP3 binding activity had no tumor-suppressor activity. Interestingly, knocking down ITGA7 ligand
laminin b1 enhanced ITGA7-TIMP3 signaling and the downstream tumor-suppressor activity, suggesting
the existence of a counterbalancing role between extracellular matrix and integrin signaling. As
a result, this report demonstrates a novel and critical signaling mechanism of ITGA7, through the
TIMP3/NF-kB/cyclin D1 pathway. (Am J Pathol 2013, 183: 831e840; http://dx.doi.org/10.1016/
j.ajpath.2013.05.010)Supported, in part, by American Cancer Society grant RSG-08-137-01-
CNE (Y.P.Y.) and National Cancer Institute grant RO1 CA098249 (J.-H.L.).Integrin a7 (ITGA7) is a member of the extracellular matrix
binding proteins. As a major class of cell adhesion molecules
in mammalian cells, integrins are involved in many cellular
processes, including development, immune responses,
leukocyte trafﬁcking, and hemostasis.1 The integrin super-
family consists of 24 members, each of which mediates
a unique function in mammals. The regulation of integrin
expression is critical for certain aspects of tissue differenti-
ation and regeneration (eg, keratinocyte differentiation, hair
follicle formation, and skeletal muscle development),2e4 and
abnormal integrin expression is associated with several
human diseases (eg, muscular dystrophy, Glanzmann’s
thrombasthenia, and congenital cardiac myopathy).4e6
ITGA7 forms a heterodimer with integrin b1 in the plasma
membrane and is responsible for communication between the
extracellular matrix and cells.7 Itga7-deﬁcient mice display
signiﬁcant hyperplasia and hypertrophy of arteries and arte-
rioles and a malformation of skeletal muscles.4,8 Recent
mutational analysis revealed ITGA7 mutations in prostate
cancer, hepatocellular carcinoma, soft tissue leiomyo-
sarcoma, and glioblastoma multiforme, with frequencies
ranging from 25% to 83%.9Many of these mutations resulted
in truncation, microdeletion, or frameshift of the protein.stigative Pathology.
.Interestingly, patients with prostate cancer or hepatocellular
carcinoma harboring ITGA7 mutations also had a higher rate
of clinical relapse.
A meta-analysis of previously published microarray
data10e15 indicated that ITGA7 was down-regulated in
nonmetastatic prostate cancer and leiomyosarcoma, but the
magnitude of the down-regulation was larger in metastatic
cancers. Also, prostate cancer and soft tissue leiomyo-
sarcoma, with focal or no ITGA7 expression, were associ-
ated with a shorter metastasis-free survival time. The forced
expression of normal ITGA7 in prostate cancer and leio-
myosarcoma cell lines suppressed tumor growth and cancer
cell migration in vitro. A mouse model of PC3 and DU145
xenograft prostate tumors showed a dramatic reduction in
tumor volume, metastatic rate, and mortality rate when
ITGA7 expression was restored. However, the molecular
mechanism of ITGA7-mediated tumor-suppressor activity
remains unclear. Herein, we report that the tissue inhibitor
of metalloproteinase 3 (TIMP3), a matrix proteinase and
a tumor suppressor, interacts with the C-terminus of ITGA7.
Tan et alWe further show that the activation of ITGA7 leads to
redistribution of NF-kB to the cytoplasm, the down-
regulation of cyclin D1, and cell growth arrest.
Materials and Methods
Cell Lines and Cell Culture
The prostate cancer cell lines, DU145 and PC3, and an
immortalized prostate epithelial cell line, RWPE-1, were
purchased from ATCC (Manassas, VA) in 2007. These cell
lines underwent one cycle of growth before being stored in
liquid nitrogen. Cells were used for transfections within 2
weeks of thawing. DU145 cells were cultured in modiﬁed
Eagle’s medium (Invitrogen, Carlsbad, CA), and PC3 cells
were cultured in F12K (Invitrogen) supplemented with 10%
fetal bovine serum (Cell Gro, Manassas), both at 37C and
5% CO2. RWPE-1 cells were cultured in keratinocyte
serum-free medium supplemented with 0.05 mg/mL bovine
pituitary extract and 5 ng/mL recombinant epidermal growth
factor (Invitrogen).
Plasmid Construction
For the construction of pBD-ITGA7c fusion proteins,
a mutagenic primer set (50-TGTGGCCTATAATCA-
TATGACCTTTCTGGAGGAGTACTCA-30 and 50-TTCA-
TTTCAAGCAAAGTCGACGCCTGGATCTGCTCTGCG-
CCCCTC-30) was designed to generate two restriction sites,
NdeI and SalI, in the C-terminal end (252 amino acids) of
ITGA7, so that the resulting PCR product could be ligated
into a pGBKT7 vector (Clontech Laboratories Inc., Moun-
tain View, CA). PCR was performed on the cDNA template
from the donor prostate (Clontech Laboratories Inc.) using
the following conditions: 94C for 1 minute, followed by 35
cycles of 94C for 30 seconds, 68C for 3 minutes, and
a ﬁnal 3-minute extension step at 68C. The PCR product
was cut with NdeI and SalI (New England Biolabs Inc.,
Ipswich, MA), gel puriﬁed, and ligated into a similarly
digested pGBKT7 vector. The fusion protein contained 156
amino acids from the ITGA7 C-terminus. A similar strategy
was used for pBD-ITGA7n (amino acid 2 to 986)
construction, except the reverse primer was replaced with
50-GCAGAATGCGGATCCCTAGCTGTTCCAGAGACG-
GCC-30. The constructs were transformed into One Shot
competent cells (Invitrogen). Plasmid DNA was extracted
from selected transformed cells and digested with NdeI and
SalI to detect the presence of the insert. The coding frame
was conﬁrmed by automated sequencing.
For construction of pGST-ITGA7, a glutathione S-trans-
ferase (GST) fusion protein, a mutagenic primer set (50-
AGGAATTCCCGGGTCGACGCCGGGGCTCGGAGCC-
GCGAC-30 and 50-AGTCACGATGCGGCCGCTGCCCC-
TGAGGAAGCCGATCCT-30) was designed to generate
SalI and NotI restriction sites within the ITGA7 coding
region that encompasses 1136 amino acids of ITGA7. PCR832was performed using these primers under the following
conditions: 94C for 1 minute, followed by 35 cycles of
94C for 30 seconds, 68C for 3 minutes, and a ﬁnal 10-
minute extension step at 68C. The PCR product was gel
puriﬁed and ligated into a pCR2.1 TA cloning vector
(Invitrogen). A similar strategy was used for constructing
pGST-ITGA7c (the forward primer sequence was 50-
AGGAATTCCCGGGTCGACGGGCAGGGGCCTGGGC-
AGAAA-30), in which 252 amino acids of the ITGA7
C-terminus were encoded. The plasmid DNA was trans-
formed into Escherichia coli. The plasmid DNA from the
selected transformants was digested with SalI and NotI and
was in frame ligated into a similarly restricted pGEX-5X-3
vector. A series of deletions, including 50 or 30 deletions, of
pGST-ITGA7c was then performed using the primer sets
described previously.16 The procedures for generating these
mutants were similar to those described for pGST-ITGA7c.
The pGST-ITGA7c and its mutants were transformed into
E. coli BL21 cells for recombinant protein production.
Yeast Transformation and Library Screening
The yeast AH109 competent cell preparation was described
previously.17 Freshly prepared AH109 competent cells (100
mL) were mixed with 0.25 to 0.50 mg pBD-ITGA7c plasmid
and 0.5 mg plasmid DNA from a prostate cDNA library
(constructed in pACT2), in 0.6 mL of polyethylene glycol/
lithium acetate, and then incubated at 30C for 30 minutes.
After this initial incubation with plasmid DNA, the cell
solution was combined with 70 mL of dimethyl sulfoxide
(Sigma, St. Louis, MO) and subjected to 15 minutes of
incubation at 42C. The cells were pelleted, resuspended
in 0.5 mL yeast peptone dextrose adenine medium, and plated
on synthetic deﬁned (SD) agar plates with different
stringency. The transformants were plated directly to the low-
(SD-Leu/-Trp), medium- (SD-Leu/-Trp/-His), or high-
stringency (SD-Ade/-His/-Leu/-Trp and X-a-Gal) plates, or
the colonies were grown on the low- and medium-stringency
plates and were then replicated onto high-stringency plates.
The grown colonies were subjected to the colony-lift ﬁlter b-
galactosidase assay, as described previously.18 pBD-53 and
pAD-T antigens were cotransformed into AH109 as positive
controls; pBD7-Lamin C and pAD-T antigens were cotrans-
formed as negative controls. pCL1 was transformed into
AH109, as a positive control for the b-galactosidase assay.
Plasmid DNA from positive clones was isolated from yeast
using the Zymoprep Yeast Plasmid Miniprep kit (Zymo
Research, Orange, CA). The plasmids were transfected into E.
coli and grown on Luria-Dulbecco agar plates with 100 mg/mL
ampicillin to select pAD-target fusion gene plasmid. The
ampicillin-resistant colonies that harbored pAD-target fusion
gene DNA were propagated in luria-bertani medium contain-
ing 100 mg/mL ampicillin. The pACT2 plasmid DNA was
puriﬁed and sequenced. Insert DNA sequences were analyzed
for nucleotide homology using National Center for Biotech-
nology Information Blast programs.ajp.amjpathol.org - The American Journal of Pathology
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Plasmid DNA from positive clones (ie, blue colonies on
high-stringency plates) were isolated from yeast, trans-
formed into E. coli, and selected with 100 mg/mL ampicillin
to obtain gene-ACT2 fusion proteins interacting with the
bait-domain fusion protein. The individual puriﬁed pACT2/
library plasmid DNA was then cotransformed with pBD-
ITGA7c, or pGBKT7 alone, into AH109 yeast cells and
grown on SD-Ade/-His/-Leu/-Trp high-stringency medium.
Colony-lift ﬁlter b-galactosidase activity was assayed on
those cells grown in this medium, and the positive clones
were sequenced.
GST Fusion Protein Pull Down
The E. coli cells harboring GST or GST-ITGA7c were grown
in 5 mL of LB with 100 mg/mL ampicillin overnight at 37C,
diluted in 20 LB, incubated with shaking until the solution
reached an OD of 0.6 to 1.0, and then induced by isopropyl-b-
D-thiogalactopyranoside (ﬁnal concentration, 1 mmol/L) for 3
hours. The cells were then pelleted, resuspended in 1 PBS,
and sonicated for 2 minutes. The proteins were solubilized in
1% Triton X-100 (Sigma-Aldrich, St. Louis, MO), centri-
fuged at 15,000  g for 5 minutes, and then the supernatant
was collected. The GST and GST-ITGA7c fusion proteins
were puriﬁed on Glutathione Sepharose 4B columns (Amer-
sham Pharmacia Biotech Inc., Piscataway, NJ). The E. coli
protein extract was pre-incubated with the column for 15
minutes at 4C and washed. The HisTAG-puriﬁed HisTAG-
TIMP3 was then incubated with GST fusion proteinepacked
Glutathione Sepharose 4B at 4C for 2 hours. The columnwas
spun at 3000  g for 1 minute and washed twice with PBS.
The protein was eluted from the column with 40 mL of SDS-
PAGE gel sample loading dye. SDS-PAGE and Western blot
analysis were subsequently conducted.
Immunoﬂuorescent Staining
RWPE1 cells were cultured on chamber slides and were
washed three times with PBS. The cells were ﬁxed with 4%
paraformaldehyde for 1 hour at room temperature. After
washing the slides twice again with PBS, the cells were
blocked with 10% donkey serum containing 0.4% Triton X-
100. The cells were then incubated with rabbit antisera
against ITGA7 and goat antisera against TIMP3 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA) at room temperature
for 1 hour. The slides were again washed twice with PBS.
Secondary antibodies from donkey directed against goat
(ﬂuorescein conjugated) and against rabbit (rhodamine
conjugated) were added and incubated at room temperature
for 1 hour. The slides were then washed twice with PBS
before the addition of DAPI. After additional washes with
PBS, slides were mounted with Prolong Gold Anti-fade
Reagent (Invitrogen). Immunoﬂuorescence staining was
examined with a confocal microscope.The American Journal of Pathology - ajp.amjpathol.orgBrdU Labeling Analysis
To perform bromodeoxyuridine (BrdU) labeling analysis, 10
mLofBrdU solution (1mmol/LBrdU in 1PBS)was added to
1 mL of tissue culture media. The treated cells were then
incubated for 3 hours at 37C. Cells were then resuspended
with 100 mL of BD Cytoﬁx/Cytoperm Buffer per sample (BD-
Pharmagen, San Jose, CA) and incubated for an additional 30
minutes at room temperature. The cells were then pelleted
and washed with 1 mL of 1 BD Perm/Wash Buffer (BD-
Pharmagen). The cells were then incubated with Cytoperm
Plus Buffer (BD-Pharmagen) for 10 minutes on ice. The
permeation procedure was repeated twice. The cells were
resuspendedwith 100 mL of dilutedDNaseI (diluted to 300 mg/
mL in Dulbecco’s PBS or 30 mg of DNaseI per tube), and
incubated for 1 hour at 37C. The cells were then washed with
1 BD Perm/Wash Buffer and incubated with 50 mL of BD
Perm/Wash Buffer containing diluted ﬂuorescent anti-BrdU
antibody (1:50) and propidium iodide for 20 minutes at room
temperature. The incubationwas thenwashedwith 1mLof 1
BD Perm/Wash Buffer. The immunoreactivity of BrdU was
assessed using an LSC-II ﬂow cytometer (BD-Pharmagen).
For siRNA analysis, 125 pmol siRNA speciﬁc for TIMP3
(50-GCAGUACAUCCAUACGGAAGCUUCC/5Phos/GG-
AAGCUUCCGUAUGGAUGUACUGCAC-30), siRNA
speciﬁc for b1-laminin (50-GAAAUGAAACUCAGCC-
UCCAGGUCCAG/5Phos/GGACCUGGAGGCUGAGU-
UUCAUUTC-30), or non-speciﬁc control (50-UAAUG-
UAUUGGAACGCAUAUU/UAUGCGUUCCAAUACA-
UUA-30) was transfected into PITT1 or PITT2 cells using
the Lipofectamine 2000 transfection kit (Invitrogen).
Immunoblots and ﬂuorescence-activated cell sorter analyses
were performed 24 hours after transfection.
Immunoblot Assays
The immunoblot procedure was previously described.9,17e25
Brieﬂy, cells were washed with PBS and lysed by radio-
immunoprecipitation assay buffer (50 mmol/L Tris-HCl at pH
7.4, 1%Nonidet P-40, 0.25% sodium deoxycholate, 150mmol/
L NaCl, 1 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl
ﬂuoride, 1 mg/mL aprotinin, 1 mg/mL leupeptin, 1 mg/mL pep-
statin, and 1 mmol/L Na3VO4). The lysates were sonicated and
centrifuged at 12,000  g at 4C for 30 minutes to remove the
insoluble materials. The proteins were separated by SDS-PAGE
in 8.5% polyacrylamide gels, and bands were blotted onto
a polyvinylidene diﬂuoride membrane. The membrane was
blocked with 5% powdered skim milk in Tris-Tween 20 buffer
(0.1 mol/L Tris-HCl and 0.1% Tween-20, pH 7.4) for 1 hour at
room temperature, followed by a 2-hour incubation with
primary anti-ITGA7 antibodies (1:500 dilution), anti-TIMP3
antibodies (1:500 dilution; Santa Cruz Biotechnology Inc.,
Dallas, TX), antietumor necrosis factor (TNF)-a antibodies
(1:500 dilution; Santa Cruz Biotechnology Inc., Santa Cruz,
CA), anti-laminin b1 antibodies (1:500 dilution; Santa Cruz
Biotechnology Inc., Santa Cruz, CA), anti-p65 antibodies833
Tan et al(1:500 dilution; Santa Cruz Biotechnology Inc., Santa Cruz,
CA), or anti-cyclin D1 antibodies (1:500 dilution; Santa Cruz
Biotechnology Inc., Santa Cruz, CA). The membrane was then
washed three times with Tris-Tween 20 buffer and incubated
with a horseradish peroxidaseeconjugated secondary antibody
speciﬁc for rabbit (anti-ITGA7; 1:1000 dilution), mouse (anti-
TIMP3, anti-p65, and antieTNF-a; 1:1000 dilution) or goat
(anti-cyclin D1 and anti-laminin b1; 1:1000 dilution) for 1 hour
at room temperature. The protein expression was detected with
the electrochemiluminescence system (AmershamLife Science,
Piscataway, NJ), according to the manufacturer’s protocols.
Colony Formation Assay
The colony formation assay was performed as previously
described.9,16e18,20,22,23,26e29 Five thousand cells were
cultured in 60-mm dishes. Triplicate experiments were
performed for each cell clone. Medium containing 10% fetal
bovine serum (Invitrogen) was changed every 4 days. On
the seventh day, the plates were stained with 1% crystal
violet and colonies with a diameter of >2 mm were counted.Chromatin Association Assay of the p65 Subunit of
NF-kB
PITT1, PITT2, C5, or C8 cells were cultured to 75% conﬂu-
ence, synchronized in serum-free medium for 24 hours, and
then treatedwith tetracycline for 24 or 48 hours. The procedure
is similar to those previously described.24,27 Cells were
washed with PBS, trypsinized, and then resuspended in 1 mL
of Buffer A (110mmol/LKC2H3O2, 15mmol/LNaC2H3O2, 2
mmol/L MgC2H3O2, 0.5 mmol/L EGTA, and 20 mmol/L
HEPES, pH 7.3). The cell suspension was treated with a ﬁnal
concentration of 2 mmol/L dithiothreital and 50 mg/mL digi-
tonin. The cells were incubated at 4C for 10 minutes in
a rotator. Nuclei were pelleted by centrifugation at 1500  g
for 10 minutes and were then resuspended in a hypotonic
buffer (Buffer B: 1 mmol/L HEPES, pH 7.5, and 0.5 mmol/L
EDTA supplemented with 0.5% NP-40). The nuclear
suspensions were then incubated at 4C for 15 minutes in
a rotator, layered onto a 10-mL sucrose cushion (100 mmol/L
sucrose and 0.5 mmol/L Tris-HCl, pH 8.5), and centrifuged at
3500  g for 15 minutes at 4C. The chromatin pellets were
suspended in 0.25 mmol/L EDTA, pH 8.0, and sonicated for
three bursts of 10 seconds each. The chromatin suspensions
were then centrifuged twice at high speed for 10 minutes at
4C, and the supernatants were retained and stored.
Results
The intracellular domain of ITGA7 is located in the C-
terminal end of the protein. To investigate the intracellular
proteins that interact with ITGA7, a yeast two-hybrid
screening analysis was performed using the 252
C-terminal amino acids of ITGA7 on a prostate cDNA834library. Thirty-seven positive clones were identiﬁed after
three rounds of metabolic screening. These clones grew in
high-stringency medium agar plates (ie, SD-Trp-Leu-Ade-
His) and were also positive for b-galactosidase activity. One
of these clones contained cDNA encoding TIMP3, a tumor
suppressor that plays a critical role in inhibiting metal-
loproteinase and blocks invasion and metastasis of cancers.
To validate this interaction, pAD-TIMP3, a plasmid that
encodes the activation domain of GAL4 fused to TIMP3,
and pBD-ITGA7c, which encodes a fusion of the DNA
binding domain of GAL4 and the ITGA7 C-terminus, were
cotransfected into yeast AH109 cells, grown in high-
stringency medium, and tested for b-galactosidase activity.
As shown in Figure 1A, TIMP3 transactivated the GAL4-
ITGA7 fusion protein and mediated the transcription of
necessary nutrients to survive in high-stringency agar and
express b-galactosidase activity. In contrast, yeast cells
transformed with pAD-Lam/pBD-ITGA7 alone did not
survive on the high-stringency agar plate (negative control)
(Figure 1A).
To investigate the binding of ITGA7 and TIMP3 in
prostate cells, co-immunoprecipitation (co-IP) assays with
ITGA7 or TIMP3 antibodies were performed using cell
lysates of RWPE1, an immortalized prostate epithelial cell
line. Immunoblot analysis indicated that TIMP3 was present
in ITGA7 co-IP complexes. Conversely, ITGA7 was
detected in TIMP3 co-IP complexes (Figure 1B). Similar
results were obtained in co-IP assays of PC3 clones with
inducible expression of ITGA7. Immunoﬂuorescence
staining of RWPE1 cells, using anti-ITGA7 and anti-TIMP3
antibodies, also detected the colocalization of these proteins
in the cytoplasm and membranous regions (Figure 1C).
We then ligated the cDNA encoding 252 amino acids at
the C-terminal end of ITGA7 into pGEX-5X-3, to generate
a GST-ITGA7c fusion protein. A cell-free HisTAG-TIMP3/
GST-ITGA7c binding analysis was then performed. The
binding assay indicated that the TIMP3 and ITGA7 C-
termini bind each other in vitro (Figure 1D). Subsequently,
we generated a series of N- and C-terminus deletion mutants
of the GST-ITGA7c fusion protein through mutational PCR.
In vitro binding assays were performed with recombinant
HisTag-TIMP3 expressed from E. coli. By overlapping the
results of the binding assays, a 67eamino acid (1037 to
1103) motif was identiﬁed as critical for the ITGA7/TIMP3
interaction (Figure 1D).
To investigate the functional signiﬁcance of the ITGA7/
TIMP3 interaction, we analyzed the effect of TIMP3 on cell
growth suppression induced by ITGA7. Because PC3 cells
have minimal endogenous expression of ITGA7, we
generated two PC3 cell clones (PITT1 and PITT2) with
inducible ITGA7 expression by transforming pCDNA4-
ITGA7/pCDNA6. We then used these clones to examine the
impact of ITGA7 expression on the cell cycle. As shown in
Figure 2, A and B, the induction of ITGA7 expression
reduced colony formation of these cells by 64% to 65%
(P < 0.001). The siRNA-mediated knockdown of TIMP3ajp.amjpathol.org - The American Journal of Pathology
Figure 1 ITGA7 binds TIMP3. A: b-Galactosidase activity of yeast harboring pBD-ITGA7c (amino acids 982 to 1138) and pAD-TIMP3, pBD-p53, and pAD-T
antigen (positive control), or pBD-ITGA7n (amino acids 2 to 986) and pAD-TIMP3 or pBD-ITGA7c and pGADT7, or pGBKT7 and pAD-TIMP3, or pGBKT7 and
pGADT7, or pBD-Lamin C and pAD-T antigen. B: Co-IP of ITGA7 and TIMP3. Proteins were extracted from RWPE1 and induced PITT1 cells (pCDNA4-ITGA7/
pCDNA6TO transfected PC3 clone). The lysates were IP with the indicated antibodies and detected by Western blot (WB) analysis with either ITGA7 or TIMP3
antibodies. Lanes 13 to 20: RWPE1- or tetracycline-induced PITT1 cells were transfected with pCMV-FLAG or pCMV-TBM-FLAG (TIMP3 binding motif-FLAG).
Immunoprecipitations and Western blot analyses were performed using the indicated antibodies. C: ITGA7 and TIMP3 colocalized in RWPE1. Immunostain-
ing was performed using antibodies speciﬁc for ITGA7 or TIMP3, as described in Materials and Methods. Original magniﬁcation,20. D: ITGA7 binds with TIMP3
in vitro. Left panel: Diagrams of GST-ITGA7c mutants. Top right panel: Binding of GST-ITGA7c fusion proteins and its mutants with puriﬁed Histag-TIMP3 from
bacterial extracts. After extensive washes, the bound proteins were eluted and immunoblotted with anti-TIMP3 antibodies. Bottom right panel: Coomassie
Brilliant Blue staining of fusion proteins.
ITGA7 Binds TIMP3largely abrogated the colony formation suppression effect
by ITGA7 (within 8% of the controls; P Z 0.12 and P Z
0.4, respectively).
The critical role of TIMP3 on cell growth suppression by
ITGA7 was also reﬂected in cell cycle analyses in which
PITT1 and PITT2 cells were induced with tetracycline,
treated with siRNA speciﬁc for TIMP3, and labeled with
BrdU. As shown in Figure 2C, the induction of ITGA7 in
PITT1 cells increased the proportion of cells in the G0/G1Figure 2 TIMP3 is essential for ITGA7-mediated suppression of cell growth. A
(pCDNA4-ITGA7/pCDNA6TO transfected PC3 clones) were induced with or without 5
or scrambled control (Scr) for 24 hours. The protein extracts were separated by S
b-actin. B: Colony formation assays of replica samples of A. Triplicate experiments
cycle analyses of replica samples of A. Triplicate experiments were performed on
The American Journal of Pathology - ajp.amjpathol.orgphase, from 46% to 76% (P < 0.001), whereas cells in the S
phase decreased, from 41% to 12% (P < 0.001). Similarly,
in PITT2 cells, the proportion of cells in G0/G1 increased,
from 45% to 75% (P < 0.001), and those in the S phase
decreased, from 42% to 11% (P < 0.001). Treatment of
these cells with siRNA speciﬁc for TIMP3 completely
abolished such effects (Figure 2C). These results suggest
that TIMP3 mediates the critical cell growth suppression
signaling by ITGA7.: Immunoblot analysis of ITGA7, TIMP3, and b-actin. PITT1 or PITT2 cells
mg/mL tetracycline (Tet) and treated with siRNA speciﬁc for TIMP3 (siTim)
DS-PAGE and immunoblotted with antibodies speciﬁc to ITGA7, TIMP3, or
were performed on each assay. **P < 0.01 (t-test). C: BrdU labeling and cell
each assay. ***P < 0.001 (t-test).
835
Figure 4 TIMP3 is required for ITGA7-induced cyclin D1 down-regulation.
PITT1 and PITT2 cells were induced with or without tetracycline (Tet) and
treated with siRNA speciﬁc for TIMP3 (siTim) or scrambled (Scr) controls for 24
hours. Lanes 1 to 8: Immunoblots were generated from the protein extracts
using antibodies speciﬁc for ITGA7, TIMP3, TNF-a, cyclin D1, or b-actin. Lanes
9 to 24: Chromatin association of p65 NF-kB subunit. PITT1 and PITT2 cells
were fractionated into chromatin (Chr) and non-chromatin (NC) fractions.
Immunoblots were generated using antibodies speciﬁc for p65, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), or histone 3.
Tan et alOne of the critical molecules that mediate TIMP3 tumor-
suppressor activity is TNF-a.30,31 To investigate the impact
of ITGA7/TIMP3 interaction on the TNF-a protein level,
immunoblot analyses using antibodies speciﬁc for TNF-a
were performed on protein extracts from PITT1 and PITT2
cells. The results indicate signiﬁcantly lower levels of TNF-
a in these cells when ITGA7 expression was induced
(Figure 3). TNF-a signaling induces translocation of NF-kB
from the cytosol to the nucleus.32 We then investigated
whether expression of ITGA7 affected the cellular distri-
bution of NF-kB by analyzing the subcellular localization of
the p65 subunit of NF-kB in PITT1 and PITT2 cells when
they were induced with tetracycline. As shown in Figure 3,
the induction of ITGA7 reduced the chromatin association
of NF-kB, while increasing its presence in the cytosol.
Consistent with the redistribution of NF-kB in these cells,
one of the main targets of NF-kB transcriptional activity,
cyclin D1, was also found to be down-regulated in ITGA7-
induced cells (Figure 3). Knockdown of TIMP3, using
TIMP3-speciﬁc siRNA, largely eliminated the redistribution
effect on NF-kB induced by ITGA7 and restored the
expression of cyclin D1 (Figure 4). These data suggest that
TIMP3 plays a key role in inhibiting the transcriptional
activity of NF-kB.
To investigate whether the interaction between ITGA7
and TIMP3 is essential for suppressing the TNF-a signaling
pathway, a mutant ITGA7 lacking the TIMP3 binding motif
(amino acids 1037 to 1103) was cloned into pCDNA4 to
generate pCDNA4-ITGA7D1037-1103. This ITGA7 mutant
was then transfected into PC3 cells to examine the impact of
such a mutation on cell growth and cell cycle progression.
In comparison with cells transduced with wild-type ITGA7,
pCDNA4-ITGA7D1037-1103etransformed PC3 clones (C5
and C8) were not growth suppressed (Figure 5) and displayed
no cell cycle inhibition (pCDNA4-ITGA7C). Furthermore,
the ITGA7 mutant had no impact on NF-kB distribution, and
did not inhibit cyclin D1 expression. These experiments
suggest that cell cycle progression and cyclin D1 expression
suppression, induced by ITGA7, are dependent on TIMP3
activation. To exclude potential allosteric or noneTIMP3-Figure 3 Induction of ITGA7 expression decreases TNF-a level and
reverses nuclear localization p65 NF-kB subunit. Lanes 1e4: Immunoblots
of ITGA7, TNF-a, cyclin D1, and b-actin from PITT1 and PITT2 cells induced
with or without tetracycline (Tet). Lanes 5e12: Chromatin association of
p65 NF-kB subunit. PITT1 and PITT2 cells were fractionated into chromatin
(Chr) and non-chromatin (NC) fractions. Immunoblots were generated
using antibodies speciﬁc for p65, glyceraldehyde-3-phosphate dehydro-
genase (GAPDH), or histone 3.
836binding related effect of motif deletion in ITGA7 on the
function of ITGA7 molecule, a fragment of cDNA corre-
sponding to ITGA7 amino acids 1037 to 1103 (in addition to
ATG start codon and 50 UTR of ITGA7) was constructed into
pCMV-FLAG to generate a TIMP3 minimal binding FLAG
(TBM-FLAG) decoy peptide to interfere with the ITGA7/
TIMP3 interaction. The results showed that the expression of
this peptide reduced ITGA7/TIMP3 binding (Figure 1B) and
signiﬁcantly reversed the cell growth inhibition and cell cycle
blocking effect of ITGA7 (Figure 6). Taken together, these
results indicate a critical role of the ITGA7/TIMP3 interac-
tion for ITGA7 tumor suppression.
Previous studies have shown that laminin plays a protec-
tive role against the cell death induced by ITGA7.16 To
investigate the impact of laminin on ITGA7-mediated cell
growth suppression, PITT1 cells were treated with siRNA
speciﬁc for b1-laminin to block the formation of the func-
tional laminin a1b1g1 complex. As shown in Figure 7, A and
B, knocking down b1-laminin exacerbated the suppression of
cell growth induced by ITGA7, in comparison with
a scrambled control (from 53% to 82%, P < 0.001), sug-
gesting that b1-laminin plays a role in moderating and
neutralizing the tumor-suppressor activity of ITGA7. Treat-
ment of sib1Lam also signiﬁcantly enhanced the cell cycle
blockade effect induced by ITGA7, increasing the proportion
of cells in G0/G1 from 76% to 89% (P < 0.001), and
decreasing cells in the S phase from 11% to 5% (P < 0.001).ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Interaction with TIMP3 is essential for ITGA7-
mediated cell growth suppression. A: Mutant ITGA7 that does
not interact with TIMP3 failed to suppress TNF-a and cyclin D1
expression and had no impact on NF-kB nuclear distribution.
Lanes 1e8: Immunoblots were generated from the pro-
tein extracts from PITT1, PITT2, or pCDNA4-ITGA7D1037-1103/
pCDNA6TO transfected PC3 clones (C5 and C8), induced with or
without tetracycline (Tet), using antibodies speciﬁc for ITGA7,
TIMP3, TNF-a, cyclin D, or b-actin. DITGA7-FLAG denotes
ITGA7-FLAG mutant that lacks amino acids 1037 to 1103 in
ITGA7 protein. Lanes 9e24: Chromatin association of p65 NF-
kB subunit. PITT1 and PITT2 cells were fractionated into
chromatin (Chr) and non-chromatin (NC) fractions. Immuno-
blots were generated using antibodies speciﬁc for p65, glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH), or histone
3. B: Colony formation assays of replica samples ofA. Triplicate
experiments were performed on each assay. C: BrdU labeling
and cell cycle analyses of replica samples of A. Triplicate
experiments were performed on each assay. **P< 0.01 (t-test).
ITGA7 Binds TIMP3Although laminin also interacts with other extracellular
matrix proteins, the most signiﬁcant effect on cell growth
from b1-laminin suppression was for cells that had concom-
itant ITGA7 induction (Figure 7, AeC). Conversely, the
effect of b1-laminin knockdown in ITGA7-negative cells
was not statistically signiﬁcant. These results suggest that
ITGA7 is the critical molecule regulating laminin survival
signals. Subsequently, we treated pCDNA4-ITGA7D1037-1103/
pCDNA6 cotransfected cells (C5) with siRNA speciﬁc for
b1-laminin and examined what role ITGA7-TIMP3 signaling
plays for extracellular matrixemediated cell growth. As
shown in Figure 7C, mutation of the TIMP3 binding site in
ITGA7 completely abrogated the effect of laminin on cell
growth and cell cycle blockade, compared with the wild-type
ITGA7, suggesting that a counterbalancing ITGA7-TIMP3
growth-suppressing signal is the main mechanism of laminin
progrowth activity.Discussion
As one of the major extracellular matrix receptors, ITGA7
forms heterodimers using its b1 chain to transduce signals
from the matrix to cells. It is well established that ITGA7 is
essential for muscle cell differentiation and migration.
Recent studies suggest that ITGA7 also plays a tumor-
suppressor role in several human malignancies.33e39
However, the signaling mechanism of ITGA7 tumor-
suppressor activity remains elusive. Our analyses in this
study suggest that TIMP3, a tumor-suppressor gene, is
a downstream signaling molecule of ITGA7. Several lines
of evidence support the ITGA7 interaction with TIMP3.
First, the C-terminus of ITGA7 binds TIMP3, both in the
yeast two-hybrid system and in cell-free in vitro binding
assays. The cell-free assays suggest that no bridge protein is
involved in the ITGA7/TIMP3 interaction. Second, both
ITGA7 and TIMP3 are readily co-immunoprecipitated fromThe American Journal of Pathology - ajp.amjpathol.orgprostate epithelial cells, by antibodies against either TIMP3
or ITGA7, suggesting the ITGA7/TIMP3 interaction occurs
intracellularly. Third, ITGA7 and TIMP3 are colocalized in
the membranous and cytoplasmic regions of immortalized
prostate epithelial cells. The TIMP3 binding motif in
ITGA7-spanning portions of transmembrane and extracel-
lular domains is intriguing. It suggests that ITGA7 may
interact with TIMP3 in the context of plasma membrane or
other plasma membraneeassociated proteins, even though
ITGA7 and TIMP3 binding is independent of other mole-
cules. It is intriguing that the TIMP3 binding site in ITGA7
may be lost in many ITGA7 mutants because it is located in
the truncated portion of the molecule.9
By identifying the ITGA7/TIMP3 interaction, this study
reveals a critical role of ITGA7 as a transmitter of signals
from the extracellular matrix to DNA replication. Extracel-
lular matrix proteins, such as laminin, are some of the most
critical ligands that maintain cell survival and growth.
Indeed, stromal components of the prostate gland are vital to
prostate gland differentiation and growth. The mechanism
for extracellular matrixemediated proproliferative activity
in prostate cancer and immortalized epithelial cells has been
elusive. This study, to our knowledge, is the ﬁrst that
identiﬁes the laminin-ITGA7-TIMP3 axis as a critical
signaling pathway for laminin-mediated cell proliferation.
TIMP3 is a natural inhibitor of the matrix metal-
loproteinases and inhibits degradation of the extracellular
matrix. TIMP3 is also a potent angiogenesis inhibitor.40,41
Mutation of TIMP3 was found in some rare congenital
vascular disorders.40,42 Unrelated to its inhibitory activity of
metalloproteinases, TIMP3 is thought to inhibit vascular
epithelial growth factoremediated angiogenesis by blocking
the binding of vascular epithelial growth factor to its receptor.
Also, the overexpression of TIMP3 induces apoptosis in
stromal cells.43e45 The ﬁnding of the TIMP3/ITGA7 inter-
action suggests that TIMP3 plays a role in regulating extra-
cellular matrix signaling. Its activation by ITGA7 leads to837
Figure 6 TIMP3 binding motif peptide interferes with cell growth suppression by ITGA7. A: Immunoblot analysis of ITGA7, TBM-FLAG, and b-actin. PITT1
and PITT2 cells were transfected with pCMV-TBM-FLAG (TIMP3 binding motif-FLAG) or vector control (V). These cells were treated with or without tetracycline
(Tet). Immunoblot assays were performed using antibodies speciﬁc for ITGA7, FLAG, or b-actin. B: Colony formation assays of duplicate experiments of A.
Triplicate experiments were performed on each assay. C: BrDU labeling and cell cycle analysis of duplicate experiments of A. Triplicate experiments were
performed on each assay. **P < 0.01 (t-test).
Tan et ala redistribution of NF-kB, from the nucleus to the cytoplasm,
and reduces the transcriptional induction of cyclin D1. The
dependency of ITGA7 on TIMP3 to down-regulate cyclin D1
and subsequently induce cell growth arrest suggests that the
ITGA7-TIMP3 signaling pathway is the main mechanism of
ITGA7-induced cell growth inhibition. Knocking down of
TIMP3 alone signiﬁcantly enhanced PC3 cell growth and
colony formation activity. It suggests that TIMP3 is a likely
downstream signaling molecule for ITGA7, and other
signaling molecules may interact and regulate TIMP3 tumor-
suppressor activity.
The current thinking is that ITGA7 is primarily involved in
smooth and skeletal muscle development; however, this
probably represents only one aspect of ITGA7’s function.
ITGA7 is expressed widely among all tissues and organs. In
a previous study, we found that ITGA7 is expressed abun-
dantly in terminally differentiated prostate acinar cells,
whereas its expression in basal cells is minimal. In terms of its838putative role in dysplasia, ITGA7 mutations were found in
multiple malignancies9 and large genome deletions encom-
passing ITGA7 were also mapped to a subset of colorectal
cancers.36 In addition, the alteration of ITGA7 expression was
found in a variety of human cancers.15 Herein, we corroborate
these ﬁndings by demonstrating that ITGA7 suppresses cell
growth. Furthermore, we show that the interaction between
laminin and ITGA7 inhibits its growth suppression signaling.
Previous studies suggest that there is a more signiﬁcant
expression of laminin 2 in acinar cell layers than in basal cells.
Based on these ﬁndings, it appears that one of the physiolog-
ical functions of ITGA7 in the prostate gland is to play
a pivotal role in preventing hyperplasia by inhibiting acinar
cell growth, especially when those cells lose contact with the
extracellular matrix. Thismay partly explain how the decrease
in ITGA7 (either by mutation or at the protein level) promotes
the development of prostate cancer, hepatocellular carcinoma,
glioblastoma multiformes, and soft tissue leiomyosarcoma.Figure 7 Laminin inhibits ITGA7-TIMP3 signaling and
growth suppression. A: Knocking down of b1-laminin
enhanced ITGA7-TIMP3 signaling. Lanes 1 to 8: Immuno-
blots were generated from the protein extracts from PITT1 and
C5 cells induced with or without tetracycline (Tet) and treated
with siRNA speciﬁc for b1-laminin (siLam) or scrambled
control (Scr), using antibodies speciﬁc for ITGA7, b1-laminin,
cyclin D1, TNF-a, or b-actin. Lanes 9 to 24: Chromatin asso-
ciation of p65 NF-kB subunit. PITT1 and C5 cells were frac-
tionated into chromatin (Chr) and non-chromatin (NC)
fractions. Immunoblots were generated using antibodies
speciﬁc for p65, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), and histone 3. B: Colony formation assays of replica
samples of A. C: BrdU labeling and cell cycle analyses of
replica samples of A. **P < 0.001.
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